Solomon Steiner
Fundador en Perosphere, Inc. .
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Sasha Bakhru | M | - |
Perosphere, Inc.
 Perosphere, Inc. Pharmaceuticals: MajorHealth Technology Perosphere, Inc. operates as a pharmaceutical company that focuses on addressing unmet medical needs associated with anticoagulant therapies. Its drug product candidate, ciraparantag, is an intravenously administered small synthetic water soluble new molecular entity rationally designed for use as a broad-spectrum reversal agent for anticoagulants including heparins and the new oral anticoagulants allowing rapid re-establishment of a normal blood coagulation state when clinically indicated. The firm's device product candidate is point-of-care coagulometer, a hand-held device that tests fresh or citrated whole blood. The system is designed for broad-spectrum monitoring of the activity of anticoagulants and their corresponding antidotes, across drug classes, in a hospital setting at a patient's bedside. The company was founded by Sasha H. Bakhru, Edith Mathiowitz, Bryan E. Laulicht and Solomon S. Steiner in 2011 and is headquartered in Danbury, CT.
Perosphere Technologies, Inc.
 Perosphere Technologies, Inc. Packaged SoftwareTechnology Services Perosphere Technologies, Inc. is a private medical technologies company that is focused on developing and commercializing the novel POC (point-of-care) coagulometer. The company is based in Danbury, CT. This diagnostic tool informs diagnosis, treatment, and prevention through precision data, made immediately accessible to all. The POC coagulometer is the only point-of-care diagnostic tool that effectively and swiftly tests clotting times across drug classes, including direct oral anticoagulants (DOACs). The fast diagnosis and related appropriate treatment decisions the POC coagulometer enables will help establish a new standard of care in hospital emergency departments for patients at risk for bleeding and has the potential to improve efficiency, provide significant cost savings, and better patient outcomes. The CEO of the company is Sasha H. Bakhru. | 13 años |
| Bryan Laulicht | M | - |
Perosphere, Inc.
Perosphere, Inc. Pharmaceuticals: MajorHealth Technology Perosphere, Inc. operates as a pharmaceutical company that focuses on addressing unmet medical needs associated with anticoagulant therapies. Its drug product candidate, ciraparantag, is an intravenously administered small synthetic water soluble new molecular entity rationally designed for use as a broad-spectrum reversal agent for anticoagulants including heparins and the new oral anticoagulants allowing rapid re-establishment of a normal blood coagulation state when clinically indicated. The firm's device product candidate is point-of-care coagulometer, a hand-held device that tests fresh or citrated whole blood. The system is designed for broad-spectrum monitoring of the activity of anticoagulants and their corresponding antidotes, across drug classes, in a hospital setting at a patient's bedside. The company was founded by Sasha H. Bakhru, Edith Mathiowitz, Bryan E. Laulicht and Solomon S. Steiner in 2011 and is headquartered in Danbury, CT.
Perosphere Pharmaceuticals, Inc.
 Perosphere Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Perosphere Pharmaceuticals, Inc. engages in the development of rescue drugs. Its pipeline include Ciraparantag, Felbamate, and Glucagon. The company is headquartered in Danbury, CT. | 13 años |
| Richard W. Gray | M | - |
New York University
| - |
| Evan Chesler | M | - |
New York University
| - |
| David Thomson | M | 57 | 22 años | |
| Philip N. Sussman | M | 72 |
Perosphere, Inc.
Perosphere, Inc. Pharmaceuticals: MajorHealth Technology Perosphere, Inc. operates as a pharmaceutical company that focuses on addressing unmet medical needs associated with anticoagulant therapies. Its drug product candidate, ciraparantag, is an intravenously administered small synthetic water soluble new molecular entity rationally designed for use as a broad-spectrum reversal agent for anticoagulants including heparins and the new oral anticoagulants allowing rapid re-establishment of a normal blood coagulation state when clinically indicated. The firm's device product candidate is point-of-care coagulometer, a hand-held device that tests fresh or citrated whole blood. The system is designed for broad-spectrum monitoring of the activity of anticoagulants and their corresponding antidotes, across drug classes, in a hospital setting at a patient's bedside. The company was founded by Sasha H. Bakhru, Edith Mathiowitz, Bryan E. Laulicht and Solomon S. Steiner in 2011 and is headquartered in Danbury, CT. | - |
| Gabriella Etmektsoglou | F | - |
New York University
| - |
| Stephen J. McCormack | M | 60 |
Cass Pharmaceuticals, Inc.
 Cass Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cass Pharmaceuticals, Inc. develops pharmaceutical products for diabetes. The company is based in Franklin, TN. The CEO of the company is Stephen J. McCormack. | - |
| Nomi Ghez | M | 78 |
New York University
| - |
| Marian Z. Stern | F | - |
New York University
| - |
| Robert Ginsberg | M | - |
New York University
| - |
| Steven Grodsky | M | - |
New York University
| - |
| Thomas R. Gerety | M | - |
New York University
| - |
| Perri Klass | M | - |
New York University
| - |
| James H. Hodge | M | - |
New York University
| - |
| William Berkley | M | 78 |
New York University
| - |
| Aristides A. N. Patrinos | M | 76 |
New York University
| - |
| Barrett Katz | M | 74 |
New York University
| - |
| Charles Aswad | M | - |
New York University
| - |
| Robert E. Baensch | M | - |
New York University
| - |
| Wayne W. Wang | M | - |
New York University
| - |
| Mark Kronenfeld | M | 69 |
New York University
| - |
| Joel Rudenstein | M | - |
New York University
| - |
| Gabriel Miller | M | - |
New York University
| 41 años |
| Dennis Crowley | M | - |
New York University
| - |
| Anthony F. Caletka | M | - |
New York University
| - |
| Hans Taparia | M | - |
New York University
| 13 años |
| Jacqueline A. French | M | - |
New York University
| - |
| Danielle Mebert | F | - |
New York University
| - |
| Hakan Üstünberk | M | - |
New York University
| - |
| Anne Tasca | F | - |
New York University
| - |
| Peter Navario | M | - |
New York University
| - |
| Trudi Bartow | F | - |
New York University
| - |
| Kevin Chen | M | 48 |
New York University
| - |
| Amit Bansal | M | - |
New York University
| 5 años |
| Bulbul Gupta | F | - |
New York University
| 9 años |
| Jui Cheng Ho | M | - |
New York University
| 4 años |
| Peggy Garry | F | - |
New York University
| - |
| Robert Holzer | M | - |
New York University
| - |
| Philip M. Tierno | M | 60 |
New York University
| 43 años |
| Carol A. Mandel | F | - |
New York University
| - |
| Jerry Shapiro | M | - |
New York University
| - |
| Jennifer van der Meer | F | - |
New York University
| - |
| Nouriel Roubini | M | 64 |
New York University
| - |
| Tina Surh | F | - |
New York University
| 19 años |
| Jon Jensen | M | - |
New York University
| - |
| Seth J. Orlow | M | - |
New York University
| - |
| Stuart Diamond | M | - |
New York University
| - |
| Matthew Messinger | M | 52 |
New York University
| - |
| Kevin R. Brine | M | 73 |
New York University
| - |
| Frank E. Richardson | M | 85 |
New York University
| - |
| Jeffrey H. Lynford | M | 77 |
New York University
| - |
| Alex Knaster | M | 65 |
New York University
| - |
| Robert Millard | M | 73 |
New York University
| - |
| Michael Steinhardt | M | 83 |
New York University
| - |
| Richard M. Hochhauser | M | 79 |
New York University
| - |
| Claire L. Gaudiani | M | 79 |
New York University
| 20 años |
| Richard Kogan | M | 81 |
New York University
| - |
| Kathleen Camilli | F | 65 |
New York University
| - |
| Ronald Blaylock | M | 64 |
New York University
| - |
| Sara Moss | F | 77 |
New York University
| - |
| Edward I. Altman | M | 83 |
New York University
| - |
| David Yakobashvili | M | 67 |
New York University
| - |
| Gary Roubin | M | 75 |
New York University
| - |
| Mitchell Rubenstein | M | 70 |
New York University
| - |
| Murray Hidary | M | - |
New York University
| - |
| Larry Fink | M | 71 |
New York University
| - |
| Joel Ehrenkranz | M | - |
New York University
| - |
| Mark Leslie | M | 77 |
New York University
| - |
| Mitchell Jacobson | M | 73 |
New York University
| - |
| Michael Klein | M | 63 |
New York University
| - |
| Kenneth Langone | M | 88 |
New York University
| - |
| David Cohen | M | 59 |
New York University
| 30 años |
| David Tanner | M | 65 |
New York University
| - |
| Stanley E. Freimuth | M | 84 |
New York University
| - |
| Lisa H. Silverstein | F | - |
New York University
| - |
| Paulo Kaiser | M | - |
New York University
| - |
| Benjamin W. Pearce | M | - |
New York University
| - |
| Ralph Alexander | M | 69 |
New York University
| - |
| Don E. Roland | M | - |
New York University
| - |
| Evangelos Simoudis | M | - |
New York University
| 6 años |
| Jaap Goudsmit | M | 73 |
New York University
| - |
| William Twyman Comfort | M | 58 |
New York University
| - |
| Steven A. Tisch | M | 74 |
New York University
| - |
| Michael C. Alfano | M | 76 |
New York University
| - |
| Mark Tercek | M | 67 |
New York University
| - |
| Steven Oyer | M | 68 |
New York University
| - |
| David Chang | M | 82 |
New York University
| 11 años |
| Charles Hinkaty | M | 73 |
New York University
| - |
| Seth M. Zachary | M | 71 |
New York University
| - |
| Joseph Landy | M | 63 |
New York University
| - |
| Robert F. Semmens | M | 66 |
New York University
| - |
| Doug Adams | M | - |
New York University
| 13 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Paul S. Bavier | M | 51 |
Biodel, Inc.
 Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 9 años |
| Joseph Himy | M | 53 |
Vyteris, Inc.
 Vyteris, Inc. Pharmaceuticals: MajorHealth Technology Vyteris, Inc. develops, manufactures and commercializes pharmaceutical products. It is engaged in the process of developing first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. The drug delivery patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. The company was founded on July 19, 2000 and is headquartered in Fair Lawn, NJ. | 7 años |
| R. Timmis Ware | M | 87 |
Pharmaceutical Discovery Corp.
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 7 años |
| Errol de Souza | M | 70 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 6 años |
| Gerard Michel | M | 60 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 7 años |
| Brian Pereira | M | 65 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 8 años |
| Ira W. Lieberman | M | 81 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | - |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 100 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Solomon Steiner
- Red Personal